FAF
ALXN

Fjarde Ap-fonden’s Alexion Pharmaceuticals ALXN Stock Holding History

Fjarde Ap-fonden’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-68,005
Closed -$12.5M – 567
2021
Q2 		$12.5M Sell
68,005
-3,100
-4% -$532K 0.11% 177
2021
Q1 		$10.9M Buy
71,105
+1,300
+2% +$201K 0.1% 207
2020
Q4 		$10.9M Sell
69,805
-7,000
-9% -$900K 0.1% 188
2020
Q3 		$8.79M Buy
76,805
+8,300
+12% +$895K 0.1% 199
2020
Q2 		$7.69M Buy
68,505
+4,600
+7% +$488K 0.1% 213
2020
Q1 		$5.74M Sell
63,905
-1,100
-2% -$108K 0.09% 212
2019
Q4 		$7.03M Buy
65,005
+4,800
+8% +$513K 0.09% 242
2019
Q3 		$5.9M Buy
60,205
+4,309
+8% +$486K 0.08% 275
2019
Q2 		$7.32M Sell
55,896
-7,100
-11% -$915K 0.09% 241
2019
Q1 		$8.52M Buy
62,996
+12,064
+24% +$1.5M 0.11% 204
2018
Q4 		$4.96M Sell
50,932
-8,100
-14% -$957K 0.09% 242
2018
Q3 		$8.21M Sell
59,032
-2,600
-4% -$326K 0.12% 185
2018
Q2 		$7.65M Buy
61,632
+349
+0.6% +$40.8K 0.12% 192
2018
Q1 		$6.83M Sell
61,283
-104
-0.2% -$12.4K 0.1% 214
2017
Q4 		$7.34M Buy
61,387
+8,916
+17% +$1.09M 0.11% 200
2017
Q3 		$7.36M Buy
52,471
+1,039
+2% +$141K 0.14% 169
2017
Q2 		$6.26M Buy
51,432
+6,879
+15% +$801K 0.13% 181
2017
Q1 		$5.4M Sell
44,553
-3,460
-7% -$446K 0.13% 180
2016
Q4 		$5.87M Sell
48,013
-4,642
-9% -$568K 0.14% 168
2016
Q3 		$6.45M Buy
52,655
+1,083
+2% +$139K 0.14% 161
2016
Q2 		$6.02M Buy
51,572
+206
+0.4% +$29.2K 0.14% 167
2016
Q1 		$7.15M Buy
51,366
+6,369
+14% +$935K 0.17% 139
2015
Q4 		$8.58M Buy
44,997
+610
+1% +$107K 0.23% 99
2015
Q3 		$6.94M Sell
44,387
-2,861
-6% -$522K 0.19% 118
2015
Q2 		$8.54M Buy
47,248
+2,532
+6% +$437K 0.21% 112
2015
Q1 		$7.75M Sell
44,716
-2,237
-5% -$405K 0.18% 131
2014
Q4 		$8.69M Sell
46,953
-3,262
-6% -$604K 0.19% 119
2014
Q3 		$8.33M Sell
50,215
-4,120
-8% -$677K 0.18% 128
2014
Q2 		$8.49M Sell
54,335
-1,992
-4% -$315K 0.17% 138
2014
Q1 		$8.57M Buy
56,327
+2,012
+4% +$320K 0.17% 137
2013
Q4 		$7.23M Sell
54,315
-3,476
-6% -$417K 0.15% 150
2013
Q3 		$6.71M Sell
57,791
-4,288
-7% -$470K 0.14% 161
2013
Q2 		$5.73M Buy
+62,079
New +$5.98M 0.12% 196

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $379M AUM 28.34% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $950M AUM 20.72% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.75B AUM 34.85% 1-Year Est. Return

Fjarde Ap-fonden's ALXN Position: Q3 2021 in Review

Fjarde Ap-fonden sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 68,005 shares — an estimated $12.5M sold.

Fjarde Ap-fonden first reported a position in ALXN in Q2 2013 and held it in 33 quarters. The position peaked at $12.5M in Q2 2021. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • Fjarde Ap-fonden reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Fjarde Ap-fonden sold 68,005 Alexion Pharmaceuticals shares in Q3 2021, an estimated $12.5M.
  • Fjarde Ap-fonden first reported a position in Alexion Pharmaceuticals in Q2 2013 and held it in 33 quarters.
  • Fjarde Ap-fonden's Alexion Pharmaceuticals position peaked at $12.5M in Q2 2021.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Fjarde Ap-fonden's 13F filing for Q3 2021, filed 15 Nov 2021.